HematologicNCT07743476
Bone Marrow Imaging and Clinical Outcomes Across Hematologic, Oncologic, and Other Relevant Conditions
An observational study of Hematologic and Oncologic, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
An observational study of patients with hematologic, oncologic, and other relevant conditions undergoing bone marrow imaging, with longitudinal collection of imaging, treatment, and clinical outcome data to characterize bone marrow features and changes over time Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Hematologic, Oncologic, Bone Marrow
- What is being tested?
- Data Collection
- How many people
- 1,000 participants
- Where
- 1 siteUnited States
- Study dates
- 31 Aug 2026to 31 Dec 2038
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: UT MD Anderson Cancer Center
Who may be able to join
- Diagnosis of a hematologic, oncologic, or other condition relevant to the study.
- Availability of clinical, imaging, laboratory, treatment, and/or outcome data relevant to the study.
- Ability to provide informed consent for prospective participation or, for pediatric participants, parent/legal guardian permission with assent when applicable.
- Participants undergoing research MRI must be eligible for MRI according to institutional safety requirements.
Who cannot join
- Inability to provide required informed consent or parental/legal guardian permission for prospective participation.
- Insufficient clinical information to support study participation
- Pregnancy.
- Contraindication to MRI will exclude participants from research-specific MRI but not necessarily from other study components.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
UT MD Anderson Cancer Center
Houston, Texas, 77030
Omran Saifi, MD, 832-829-0337, OSaifi@mdanderson.org
Omran Saifi, MD
About this study
An observational study of patients with hematologic, oncologic, and other relevant conditions undergoing bone marrow imaging, with longitudinal collection of imaging, treatment, and clinical outcome data to characterize bone marrow features and changes over time
Read the detailed description
Primary Objective
To establish a longitudinal cohort integrating bone marrow imaging with clinical and treatment-related data.
Primary Endpoint
Successful enrollment of eligible participants and collection of relevant imaging and clinical data.
Secondary Objective
- Characterize bone marrow imaging findings across relevant patient populations.
- Evaluate relationships between imaging findings, treatment exposures, hematologic recovery, treatment-related toxicities, and clinical outcomes.
- Assess longitudinal changes in bone marrow imaging findings over time and following cancer therapy.
- Explore associations between imaging findings and laboratory, pathology, and research biomarker data when available.
- Conditions
- Hematologic, Oncologic, Bone Marrow
- Being tested
- Data Collection
- Keywords
- Bone Marrow Imaging, Bone Marrow Assessment, Hematologic Malignancies, Cancer Therapy, Treatment-Related Marrow Injury
- Medical subject headings
- Neoplasms, Hematologic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Data CollectionOther
Clinical, imaging, laboratory, treatment, and outcome data will be collected from institutional records and research assessments, as applicable.
What is being measured
The primary outcome is the main question the study is designed to answer.
Bone marrow imaging characteristics.
Evaluation of bone marrow imaging findings and longitudinal changes in patients with hematologic, oncologic, and other relevant conditions.
Measured: Through study completion; an average of 1 year.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Aug 2026
- Study start31 Aug 2026
- Primary completion31 Dec 2036 (estimated)
- Study completion31 Dec 2038 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HematologicStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Omran Saifi, MD, Principal investigator, UT MD Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07743476
- Sponsor's protocol ID
- 2026-0958
- Other IDs
- NCI-2026-05811
- Status last verified
- Sep 2026
- First submitted
- 30 Jul 2026
- Last updated
- 18 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bone Marrow Imaging and Clinical Outcomes Across Hematologic, Oncologic, and Other Relevant Conditions
- ClinicalTrials.gov ID
- NCT07743476
- Acronym / sponsor ID
- 2026-0958
- Conditions
- Hematologic, Oncologic, Bone Marrow
- Keywords
- Bone Marrow Imaging, Bone Marrow Assessment, Hematologic Malignancies, Cancer Therapy, Treatment-Related Marrow Injury
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Study start
- 31 Aug 2026 (actual)
- Primary completion
- 31 Dec 2036 (estimated)
- Study completion
- 31 Dec 2038 (estimated)
- First posted
- 4 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
An observational study of patients with hematologic, oncologic, and other relevant conditions undergoing bone marrow imaging, with longitudinal collection of imaging, treatment, and clinical outcome data to characterize bone marrow features and changes over time
Detailed description
Primary Objective
To establish a longitudinal cohort integrating bone marrow imaging with clinical and treatment-related data.
Primary Endpoint
Successful enrollment of eligible participants and collection of relevant imaging and clinical data.
Secondary Objective
- Characterize bone marrow imaging findings across relevant patient populations.
- Evaluate relationships between imaging findings, treatment exposures, hematologic recovery, treatment-related toxicities, and clinical outcomes.
- Assess longitudinal changes in bone marrow imaging findings over time and following cancer therapy.
- Explore associations between imaging findings and laboratory, pathology, and research biomarker data when available.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- UT MD Anderson Cancer Center
Key inclusion criteria (4 listed)
- Diagnosis of a hematologic, oncologic, or other condition relevant to the study.
- Availability of clinical, imaging, laboratory, treatment, and/or outcome data relevant to the study.
- Ability to provide informed consent for prospective participation or, for pediatric participants, parent/legal guardian permission with assent when applicable.
- Participants undergoing research MRI must be eligible for MRI according to institutional safety requirements.
Key exclusion criteria (4 listed)
- Inability to provide required informed consent or parental/legal guardian permission for prospective participation.
- Insufficient clinical information to support study participation
- Pregnancy.
- Contraindication to MRI will exclude participants from research-specific MRI but not necessarily from other study components.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Data CollectionClinical, imaging, laboratory, treatment, and outcome data will be collected from institutional records and research assessments, as applicable. | Other | – |
Primary outcome
Bone marrow imaging characteristics.
Time frame: Through study completion; an average of 1 year.
Evaluation of bone marrow imaging findings and longitudinal changes in patients with hematologic, oncologic, and other relevant conditions.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2026.
- UT MD Anderson Cancer CenterLink provided by the sponsor.
Related trials for Hematologic
RecruitingPhase 2
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
Not yet recruiting
The AYA Oncology Self-care Movement
Acute Lymphobkastic Leukemia, Medication Adherence
RecruitingPhase 1
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency
Inherited Bone Marrow Failure Syndrome, Familial Platelet Disorder With Predisposition to Myeloid Malignancies
RecruitingPhase 2
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Immune Thrombocytopenia
RecruitingObservational study
A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapsed or Refractory
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Omran Saifi, MD principal investigator
UT MD Anderson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hematologic and Oncologic, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Omran Saifi, MD (832-829-0337, OSaifi@mdanderson.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Bone marrow imaging characteristics. (time frame: Through study completion; an average of 1 year.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2026.